A Study Evaluating FMC-376
Phase 1/2
403
about 4.2 years
18+
15 sites in CA, FL, IN +7
About this study
Researchers are testing a treatment called FMC-376 for people with certain types of advanced solid tumors that have KRAS G12C mutations. The trial will involve different dose levels and last approximately 1540 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take FMC-376
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Adverse Events (AEs), Dose Limiting Toxicities
Secondary: Area Under Blood Concentration-Time Curve (AUC) of FMC-376, Clearance (CL) of FMC-376 from Blood Plasma, Disease Control Rate (DCR), Duration of Response (DOR), Elimination Half-life (t1/2) of FMC-376, Maximum Observed Plasma Concentration (Cmax) of FMC-376, Overall Response Rate (ORR), Overall Survival (OS)
Oncology